|Bid||21.93 x 1200|
|Ask||22.88 x 1200|
|Day's Range||22.39 - 22.92|
|52 Week Range||6.25 - 23.19|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD) will be pleased this week, given that the stock price is up...
Thank you for joining our conference call to discuss Amicus Therapeutics' third quarter 2020 financial results and corporate highlights. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; Dr. Jeff Castelli, Chief Development Officer; and Dr. Mitch Goldman, Senior Vice President of Clinical Research.